

Supplementary material

- S1. Ono C, Hsyu PH, Abbas R, et al. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions. *Drug Metab Dispos.* 2017;45:390-98.
- S2. Li J, Chen J, Kanamaluru V, Gaemers SJM, et al. Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1. *Mol Genet Metab.* 2020;129:117-24.
- S3. Tse S, Dowty ME, Menon S, et al. Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib. *J Clin Pharmacol.* 2020;60:1617-28.
- S4. Ghoneim A, Mansour S. The Effect of Liver and Kidney Disease on the Pharmacokinetics of Clozapine and Sildenafil: A Physiologically Based Pharmacokinetic Modeling. *Drug Des Devel Ther.* 2020;14:1469-79.
- S5. Muirhead G, Wilner K, Colburn W, et al. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. *Br J Clin Pharmacol.* 2002; 53 Suppl 1:21S-30S.
- S6. Sun L, Barter Z, von Moltke L, et al. Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet. *CPT Pharmacometrics Syst Pharmacol.* 2021 Sep;10(9):1071-1080.
- S7. Wu X, Zhang X, Xu R, et al. Physiologically based pharmacokinetic modelling of tadalafil after intravenous injection and extended-release oral tablet administration in healthy volunteers: An extrapolation to other patient populations including patients with hepatic impairment. *Br J Clin Pharmacol.* 2021 Jun 30.
- S8. Nguyen L, Holland J, Ramies D, et al. Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib. *J Clin Pharmacol.* 2016;56:1130-40.
- S9. Gerner B, Scherf-Clavel O. Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug-Drug Interaction with Rifampin and Liver Impairment. *Pharmaceutics.* 2021;13:778.
- S10. Huang W, Nakano M, Sager J, et al. Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions. *Drug Metab Dispos.* 2017;45:1156-65.
- S11. Alsmadi MM, Al-Daoud NM, Jaradat MM. Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment. *Biopharm Drug Dispos.* 2021;42:263-84.
- S12. Li R, Barton HA, Maurer TS. A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates Under Liver Cirrhosis Conditions. *CPT Pharmacometrics Syst Pharmacol.* 2015;4:338-49.
- S13. Ogawa SI, Shimizu M, Yamazaki H. Modelled plasma concentrations of pemafibrate with co-administered typical cytochrome P450 inhibitors clopidogrel, fluconazole or clarithromycin predicted by physiologically based pharmacokinetic

- modelling in virtual populations. *Xenobiotica*. 2020;50:1413-22.
- S14. El-Khateeb E, Achour B, Al-Majdoub ZM, et al. Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment. *Mol Pharm*. 2021;18:3563-77.
- S15. Huang H, Xie H, Chaphekar N, et al. A physiologically based pharmacokinetic analysis to predict the pharmacokinetics of intravenous isavuconazole in patients with or without hepatic impairment. *Antimicrob Agents Chemother*. 2021;65:e02032-20.
- S16. Ladumor M, Storelli F, Liang X, et al. Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes. *CPT Pharmacometrics Syst Pharmacol*. 2022;00:1-13.
- S17. Chen Y, Ke M, Xu J, Lin C. Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling. *AAPS Pharm Sci Tech*. 2020;21:98.
- S18. Scheen A. Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor. *Clin Pharmacokinet* 2014;53:213-25.
- S19. Flanagan S, Minassian S, Morris D, et al. Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment. *Antimicrobial Agents and Chemotherapy*. 2014;58: 6471-76.
- S20. Cinacalcet: FDA Clinical Pharmacology and Biopharmaceutics Review(s). Application Number 21-688, 2003.
- S21. Bradley-Kroth Pharmacokinetics and Safety of a Single Intravenous Dose of the Antibiotic Tigecycline in Patients With Cirrhosis. *J Clin Pharmacol* 2010;51:93-101.
- S22. Veronese L, Rautureau J, Sadler B, et al. Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function. *Antimicrobial Agents and Chemotherapy*. 2000;44:821-26.
- S23. Bruderer S, Detishin V, Tsvitbaum N, Dingemans J. Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan. *Br J Clin Pharmacol*. 2011;71:52-60.
- S24. El-Khoueiry A, Posey JA, Castillo Ferrando JR, Krishnamurthi SS, Syed S, Kollia G, Walters I, Fischer BS, Masson E. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. *Cancer Chemother Pharmacol*. 2013 Jul;72(1):53-64.
- S25. Preston R, Marbury T, Balratnam G, et al. Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment. *J Clin Pharmacol* 2021;61:493-505.
- S26. Magee M, Slater J, Mannino F, et al. Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir. *J Clin Pharmacol* 2021;61:939-53.
- S27. Barbour A, Rockich K, Cimino E, et al. Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib. *J Clin Pharmacol* 2021;61:954-60.
- S28. Samant T, Yang S, Miller M, et al. Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment. *J Clin Pharmacol* 2021;61:1001-9.

- S29. Taylor L, Crockett J, Tayo B, et al. A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment. *J Clin Pharmacol* 2019;59:1110-19.
- S30. Marbury T, Fox J, Kaelin B, et al. Pharmacokinetics of conivaptan use in patients with severe hepatic impairment. *Drug Design, Development and Therapy* 2017;11 373-82.
- S31. Small D, Zhang W, Royalty J, et al. Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib. *Eur J Clin Pharmacol.* 2016;72:563-72.
- S32. Hossain M, Tiffany C, Tao Y, et al. Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment. *Clin Pharmacol Drug Develop.* 2021;10:588-97.
- S33. Blake JC, Palmer JL, Minton N, et al. The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment. *Br J Clin. Pharmac.* 1993;35:441-43.
- S34. Grechko N, Skarbova V, Tomaszewska K, et al. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment. *Cancer Chemotherapy and Pharmacology.* 2021;88:259-70.
- S35. Tomkinson H, Kemp J, Oliver S, et al. Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies. *BMC Clinical Pharmacology.* 2011;11:1-11.
- S36. Hoch M, Sato M, Zack J, et al. Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment. *J Clin Pharmacol* 2021;61:1454-65.
- S37. Sane R, Malhi V, Sutaria D, et al. Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function. *J Clin Pharmacol* 2022;62:171-81.
- S38. Malhotra BK, Schoenhard GL, de Kater AW, Friedmann N. The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. *J Opioid Manag.* 2015;11:157-69.
- S39. Pique J, Feu F, Prada G, et al. Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. *Clin Pharmacokinet.* 2002;41:999-1004.
- S40. Zapater P, Vega M, Horga J, et al. Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. *Aliment Pharmacol Ther* 2004;20:29-36.
- S41. Li Y, Wang X, Liu L, et al. An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics. *Clin Pharmacol Drug Develop.* 2019;8:346-54.
- S42. Boinpally R, Jakate A, Butler M, et al. Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial. *Clin Pharmacol Drug Develop.* 2021;10:726-73.